Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Ribociclib tablets (Kisqali) - selected U.S. label sections
Product / population
KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.
Renal method
eGFR in mL/min/1.73 m2; severe category as specified by the label.
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Official
Ribociclib tablets (Kisqali) - selected U.S. label sections
U.S. product labeling / DailyMed · KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.
Renal method: eGFR in mL/min/1.73 m2; severe category as specified by the label. Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Renal dose comments
Mild or moderate renal impairment does not require adjustment. For severe impairment, the recommended starting dose is 200 mg once daily. Preserve the treatment cycle of 21 days on treatment followed by 7 days off, rather than converting this into continuous daily therapy.
RDM32-ribociclib-kisqali-1 · Source locator: 2.1; 2.2, Severe Renal Impairment; 8.7
Scope and monitoring
The concomitant endocrine therapy, toxicity modifications, ECG and electrolyte monitoring remain separate requirements. This summary does not assign a hemodialysis regimen.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.